Ikena Oncology, Inc. — FY 2023 Form 10-K
Entity note: The request metadata names Imagenebio, Inc., but the supplied filing is for Ikena Oncology, Inc. (Nasdaq: IKNA). This summary covers the fiscal year ended December 31, 2023; the filing was signed March 12, 2024.
Business context
Ikena is a clinical-stage oncology company with no approved products and no product-sales revenue. Its lead programs are IK-930, a TEAD1 inhibitor in Phase 1 testing, and IK-595, a MEK-RAF inhibitor whose Phase 1 trial dosed its first patient in December 2023. The company reported that it plans to focus resources on these programs.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Collaboration revenue | $9.2 million | $15.6 million |
| Research and development expense | $59.7 million | $64.3 million |
| General and administrative expense | $24.9 million | $22.2 million |
| Total operating expenses | $84.6 million | $86.5 million |
| Operating loss | $75.4 million | $70.9 million |
| Net loss | $68.2 million | $68.8 million |
| Net loss per share, basic and diluted | $1.63 | $1.90 |
| Net cash used in operating activities | $79.7 million | $74.1 million |
Revenue came from the Bristol Myers Squibb (BMS) collaboration, not product sales. With no product sales, a product gross margin is not applicable; the filing does not present a product-sales margin. Investment income was $7.1 million, compared with $2.1 million in 2022, helping net loss remain nearly flat despite a larger operating loss.
At year-end, cash and cash equivalents were $119.9 million and marketable securities were $55.6 million, totaling $175.5 million. Current assets were $178.7 million and current liabilities $14.2 million. Total liabilities were $22.3 million, including $10.7 million in operating lease liabilities; the filing does not report conventional borrowings. Management estimated the year-end liquidity would fund operations into the second half of 2026, incorporating the planned 2024 workforce reduction.
Operating cash use increased by $5.6 million year over year. Investing activities provided $64.1 million, mainly reflecting marketable-security sales and maturities; financing activities provided $76.0 million, including $37.4 million net proceeds from the May 2023 stock offering and cash acquired with Pionyr.
Changes and significant events
- Collaboration revenue fell 41% as manufacturing work on IK-412 substantially completed in 2022. R&D expense declined 7%, principally due to lower IK-175 and early-program spending; G&A increased 12%, including a $1.7 million impairment of the acquired San Francisco lease right-of-use asset.
- Net loss improved by $0.6 million, while operating loss increased by $4.5 million. Weighted-average shares rose to 41.7 million from 36.2 million, and the reported loss per share narrowed to $1.63 from $1.90.
- The August 2023 Pionyr acquisition brought approximately $48.0 million in net assets, primarily cash and securities, and added a vacant San Francisco lease. Ikena is seeking a subtenant. The acquisition also included contingent value rights entitling former Pionyr holders to 50% of net proceeds, excluding royalties, from potential monetization of legacy programs within two years.
- In January 2024, BMS declined to opt into IK-175 and did not exercise its option for IK-412. Ikena regained global rights but said it would not fund further clinical development of those programs and would pursue partnering or other business-development options.
Outlook, clinical updates, and risks
- In January 2024, the board approved a workforce reduction of approximately 35% (about 20 employees), focused on aligning operations with IK-930 and IK-595. The company expected about $1.6 million in cash severance costs and completion by March 31, 2024.
- For IK-930, preliminary data reported in November 2023 covered 26 dose-escalation patients as of October 31. Three had treatment-related proteinuria, all reversible and low grade; one dose-limiting toxicity was reported, a grade 3 liver-enzyme elevation in an EHE patient with significant liver metastases. The maximum tolerated dose had not been reached. Among seven EHE patients, all had stable disease as best response, three had tumor shrinkage, and four reported symptomatic improvement. These are early, limited data, not evidence of established clinical benefit.
- IK-930 exposure varied with the original formulation; the company reported improved, less variable exposure in initial cohorts using formulation B. Additional monotherapy data were expected in the second half of 2024, and a combination study with AstraZeneca’s osimertinib was planned.
- For IK-595, the first Phase 1 patient was treated in December 2023; the first cohort cleared its initial safety window in January 2024. Clinical dose escalation was ongoing. Claims of differentiated efficacy and therapeutic window are based on preclinical evidence and company expectations.
- Management cautions that substantial losses and negative operating cash flow are expected to continue, and additional funding may be needed. The runway estimate is subject to assumptions; financing may be unavailable or dilutive. Other key risks include early-stage clinical uncertainty, patient enrollment and biomarker testing, reliance on third-party manufacturers and CROs, single-source API supply, competition, and intellectual-property challenges.
Investor facts to verify
- Confirm the company identity: the supplied filing is Ikena Oncology, Inc., not Imagenebio, Inc.
- Review the full audited statements and notes for cash burn, lease commitments, and the assumptions behind the stated second-half-2026 runway.
- Track the 2024 workforce reduction, severance costs, and whether the expected cost savings are achieved.
- Assess subsequent IK-930 and IK-595 trial data, including safety, exposure, dose selection, and whether preliminary responses translate into durable clinical benefit.
- Verify progress on the osimertinib combination and on partnering or monetization plans for IK-175, IK-412, and Pionyr legacy assets.